Adaptive Biotechnologies (NASDAQ:ADPT) is a biotech firm specializing in the genetics of the adaptive immune system to develop clinical products and services aimed at diagnosing, treating, and managing diseases more precisely. The company leverages its proprietary immune medicine platform to decode the information carried by the immune system, harnessing it for medical diagnosis and treatment, particularly in cancer, autoimmune conditions, and infectious diseases. With a focus on innovative research and development, Adaptive Biotechnologies is committed to advancing the understanding of the immune system’s role in health and disease, aiming to improve patient outcomes through precision medicine. Their projects range from clinical diagnostics to drug discovery, striving to translate the complexity of the immune system into actionable solutions for patients and healthcare providers.